This is a 5 year, Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis.
ESPRIT is a 10 year registry of patients taking HUMIRA® for Psoriasis. Patients who volunteer to participate will be asked to provide information about their medical history and experiences with HUMIRA®. No registry specific testing will be performed. Patients will be asked to provide data on their experiences with HUMIRA® approximately every 6 months, or as determined by the study doctor. No drug will be provided as a result of participation in the registry. All treatment decisions are independent of participation in the registry. This is an ongoing trial, but we are no longer enrolling.
A Phase IV observational study that compares systemic psoriasis therapies that are available for prescription
Abbvie Protocol H15-457: Cross-sectional Observational Study Evaluating Clinical Specialty Setting as Determinant of Management in Patients with Psoriatic Arthritis- ACTIVE
A Phase IV observational study evaluating the role of different physician specialties (Rheumatologist, Dermatologist, and Primary Care Physician) in the management of Psoriatic Arthritis.
The Clinical Research team at DermAssociates is committed to conducting clinical research in accordance with Good Clinical Practices and IHCP guidelines to ensure the trials are carried out safely and ethically. DermAssociates consistently seeks optimal results for its patients and has a proven record of meeting and exceeding expectations.
To learn more about our clinical trials, contact us at: 301-355-3183